Details of Drug-Metabolizing Enzyme (DME)

General Information of DME (ID: DME1465)
DME Name Cytochrome P450 102D1 (cyp102), Streptomyces avermitilis
Synonyms Cytochrome P450 family 102 subfamily D member 1; Flavocytochrome P450 102D1; P450 102D1; cyp102D1
Gene Name cyp102A1
UniProt ID
CPXB_BACMB
Gene ID
29911283
EC Number    EC: 1.14.14.1     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.1
Lineage    Species: Streptomyces avermitilis     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Actinobacteria
Class: Actinobacteria
Order: Streptomycetales
Family: Streptomycetaceae
Genus: Streptomyces
Species: Streptomyces avermitilis
Interactome
(loading-time for this interactome depdends on the speed of web connection)
       Interactions between Host Protein and DME (HOSPPI)                     
Jump to Detailed Interactome Data                      
      Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME
Tissue Distribution Primarily distributed in human gut.
Sequence
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIK
EACDESRFDKNLSQALKFVRDFAGDGLFTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMM
VDIAVQLVQKWERLNADEHIEVPEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVR
ALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKASGEQSDDLLTHMLN
GKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLV
DPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQ
LHRDKTIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLK
HFDFEDHTNYELDIKETLTLKPEGFVVKAKSKKIPLGGIPSPSTEQSAKKVRKKAENAHN
TPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTASYNGH
PPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIAD
RGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMH
GAFSTNVVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFG
LDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVE
LEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDE
KQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPETPLI
MVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIIT
LHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYAD
VHQVSEADARLWLQQLEEKGRYAKDVWAG
Structure
1BU7 ; 1BVY ; 1FAG ; 1FAH ; 1JME ; 1JPZ ; 1P0V ; 1P0W ; 1P0X ; 1SMI ; 1SMJ ; 1YQO ; 1YQP ; 1ZO4 ; 1ZO9 ; 1ZOA ; 2BMH ; 2HPD ; 2IJ2 ; 2IJ3 ; 2IJ4 ; 2J1M ; 2J4S ; 2NNB ; 2UWH ; 2X7Y ; 2X80 ; 3BEN ; 3CBD ; 3DGI ; 3EKB ; 3EKD ; 3EKF ; 3HF2 ; 3KX3 ; 3KX4 ; 3KX5 ; 3M4V ; 3NPL ; 3PSX ; 3WSP ; 4DQK ; 4DQL ; 4DTW ; 4DTY ; 4DTZ ; 4DU2 ; 4DUA ; 4DUB ; 4DUC ; 4DUD ; 4DUE ; 4DUF ; 4H23 ; 4H24 ; 4HGF ; 4HGG ; 4HGH ; 4HGI ; 4HGJ ; 4KEW ; 4KEY ; 4KF0 ; 4KF2 ; 4KPA ; 4KPB ; 4O4P ; 4RSN ; 4WG2 ; 4ZF6 ; 4ZF8 ; 4ZFA ; 4ZFB ; 5B2U ; 5B2V ; 5B2W ; 5B2X ; 5B2Y ; 5DYP ; 5DYZ ; 5E78 ; 5E7Y ; 5E9Z ; 5JQ2 ; 5JQU ; 5JQV ; 5JTD ; 5OG9 ; 5UCW ; 5XA3 ; 5XHJ ; 5ZIS ; 5ZLH ; 6H1O ; 6H1S ; 6IAO
Pathway Aminobenzoate degradation (bmeg00627 )
Fatty acid degradation (bmeg00071 )
Microbial metabolism in diverse environments (bmeg01120 )
Tryptophan metabolism (bmeg00380 )
Function This enzyme is P-450 heme-thiolate protein, acting on a wide range of substrates including many xenobiotics, steroids, fatty acids, vitamins and prostaglandins; reactions catalysed include hydroxylation, epoxidation, N-oxidation, sulfooxidation, N-, S- and O-dealkylations, desulfation, deamination, and reduction of azo, nitro and N-oxide groups.
Full List of Drug(s) Metabolized by This DME
      Drugs Approved by FDA Click to Show/Hide the Full List of Drugs:          1 Drugs
Meclofenamic acid
 Drug Info Approved Myalgia ICD11: FB56 [1]
      Drugs in Phase 4 Clinical Trial Click to Show/Hide the Full List of Drugs:          1 Drugs
Daidzein
 Drug Info Phase 4 Dyslipidaemia ICD11: 5C81 [2], [3]
      Preclinical/investigative Agents Click to Show/Hide the Full List of Drugs:          1 Drugs
Coumarin
 Drug Info Investigative Discovery agent ICD: N.A. [2], [4]
      Experimental Enzyme Kinetic Data of Drugs Click to Show/Hide the Full List of Drugs:          1 Drugs
Daidzein
 Drug Info Phase 4 Dyslipidaemia Kcat/Km = 0.28 s-1microM-1 [2], [3]
Full List of Metabolic Reactions (MR) Catalyzed by This DME
MR ID Reactant Product MR Type Source Drug REF
MR000651 Chlorzoxazone 6-hydroxychlorzoxazone Oxidation - 6-Hydroxylation Chlorzoxazone [5], [6], [7]
MR001828 Omeprazole sulfone metabolite 5'-OH omeprazole sulfide metabolite Oxidation - Hydroxylation Omeprazole [8]
References
1 Both Reactivity and Accessibility Are Important in Cytochrome P450 Metabolism: A Combined DFT and MD Study of Fenamic Acids in BM3 Mutants J Chem Inf Model. 2019 Feb 25;59(2):743-753. doi: 10.1021/acs.jcim.8b00750.
2 The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
3 Engineering of daidzein 3'-hydroxylase P450 enzyme into catalytically self-sufficient cytochrome P450. Microb Cell Fact. 2012 Jun 14;11:81.
4 Cloning, expression and characterization of CYP102D1, a self-sufficient P450 monooxygenase from Streptomyces avermitilis. FEBS J. 2012 May;279(9):1650-62.
5 Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity Br J Clin Pharmacol. 2004 Aug;58(2):190-200. doi: 10.1111/j.1365-2125.2004.02132.x.
6 Amalgamation of in-silico, in-vitro and in-vivo approach to establish glabridin as a potential CYP2E1 inhibitor. Xenobiotica. 2021 Jun;51(6):625-635. doi: 10.1080/00498254.2021.1883769.
7 Generation and Characterization of CYP2E1-Overexpressing HepG2 Cells to Study the Role of CYP2E1 in Hepatic Hypoxia-Reoxygenation Injury. Int J Mol Sci. 2023 May 1;24(9):8121. doi: 10.3390/ijms24098121.
8 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.